Skip to main content
Clinical Trials/NCT01372709
NCT01372709
Completed
N/A

A Post-Market Study to Evaluate the Safety and Performance of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System

TriVascular, Inc.30 sites in 8 countries501 target enrollmentMay 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Abdominal Aortic Aneurysm
Sponsor
TriVascular, Inc.
Enrollment
501
Locations
30
Primary Endpoint
Treatment Success at 12 Months Post-Implantation/surgery.
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is a prospective observational post-market study of subjects receiving the Ovation™ or Ovation Prime™ Abdominal Stent Graft System ("Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market Study") in the treatment of abdominal aortic aneurysms (AAA). The Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market study is intended to expand the clinical knowledge base by collecting data on subjects treated with the Ovation™ or Ovation Prime™ Abdominal Stent Graft System in actual clinical practice following commercial approval.

Registry
clinicaltrials.gov
Start Date
May 2011
End Date
June 14, 2019
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is \> 18 years or minimum age as required by local regulations.
  • Indication for elective repair of AAA with an endovascular stent graft in accordance with the Instructions for Use of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System.
  • Subject has signed an Ethics Committee (EC) approved Informed Consent Form. The subject or legal representative has been informed of the nature of the study, has consented to participate, and has authorized the collection and release of his/her medical information.
  • Subject intends to electively receive the Ovation™ or Ovation Prime™ Abdominal Stent Graft System.
  • Subject has the ability and willingness to comply with all follow-up exams as indicated in clinical investigation plan.

Exclusion Criteria

  • Subject demonstrates high probability of non-adherence to physician's follow-up requirements.
  • Subject's current participation in a concurrent randomized control trial (RCT) or investigational device/drug study which could confound study results.
  • Life expectancy less than 1 year
  • Pregnancy
  • Subjects with poor renal function as indicated by a serum creatinine \> 2.5mg/dl.

Outcomes

Primary Outcomes

Treatment Success at 12 Months Post-Implantation/surgery.

Time Frame: 12 Months

The primary endpoint is treatment success at 12 months post-implantation/surgery. Treatment success is defined as a composite technical endpoint composed of successful introduction and deployment of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System at the initial implantation procedure along with clinical endpoints of absence from type I or III endoleaks, aneurysm expansion, aneurysm rupture, conversion to open surgical repair, graft migration, and graft occlusion at 12 months post-implantation procedure.

Secondary Outcomes

  • Safety and Performance Endpoints(1, 6, &12 Months)

Study Sites (30)

Loading locations...

Similar Trials